“When My Information Changes, I Alter My Conclusions.” What Can We Learn From the Failures to Adaptively Respond to the SARS-CoV-2 Pandemic and the Under Preparedness of Health Systems to Manage COVID-19?

Document Type : Viewpoint

Authors

1 School of Public Health, Université libre de Bruxelles, Brussels, Belgium

2 Global Health Theme, University of Leeds, Leeds, UK

3 Deutsche Gesellschaft für Internationale Zusammenarbeit, Kinshasa Country Office, Kinshasa, Democratic Republic of the Congo

4 Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

5 CEPED, Institute for Research on Sustainable Development (IRD), IRD-Université de Paris, Paris, France

6 School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW, Australia

Keywords


Introduction

Countries around the world have been hit by the severe acute respiratory syndrome coronavirus 2/coronavirus disease 2019 (SARS-CoV-2/COVID-19) pandemic, and have reacted to its spread in very different ways. Some countries (eg, Sweden) have implemented minimalist public health interventions, while others (eg, France, New Zealand) have imposed almost complete population lock-downs and/or other restrictions to freedom of movement and privacy.1 Such extreme interventions have complex impacts and come at a tremendous (mental) health and societal cost, disproportionately affecting the lowest socio-economic strata, and populations in low-and middle-income countries.2-5 However, the patterns of infection and mortality rates are extremely heterogeneous within and across individuals and countries.6,7... (Read more...)

 

  1. University of Oxford, Blavatnik School of Government. Coronavirus Government Response Tracker. https://www.bsg.ox.ac.uk/research/research-projects/coronavirus-government-response-tracker. Accessed August 17, 2020. Published August 6, 2020.
  2. Shadmi E, Chen Y, Dourado I, et al. Health equity and COVID-19: global perspectives. Int J Equity Health. 2020;19(1):104. doi:10.1186/s12939-020-01218-z
  3. Hogan AB, Jewell BL, Sherrard-Smith E, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health. 2020;8(9):e1132-e1141. doi:10.1016/s2214-109x(20)30288-6
  4. Galea S, Merchant RM, Lurie N. The mental health consequences of COVID-19 and physical distancing: the need for prevention and early intervention. JAMA Intern Med. 2020;180(6):817-818. doi:10.1001/jamainternmed.2020.1562
  5. Bambra C, Riordan R, Ford J, Matthews F. The COVID-19 pandemic and health inequalities. J Epidemiol Community Health. 2020;74(11):964-968. doi:10.1136/jech-2020-214401
  6. Adhikari S, Pantaleo NP, Feldman JM, Ogedegbe O, Thorpe L, Troxel AB. Assessment of community-level disparities in coronavirus disease 2019 (COVID-19) infections and deaths in large US metropolitan areas. JAMA Netw Open. 2020;3(7):e2016938. doi:10.1001/jamanetworkopen.2020.16938
  7. Van Damme W, Dahake R, Delamou A, et al. The COVID-19 pandemic: diverse contexts; different epidemics-how and why? BMJ Glob Health. 2020;5(7): e003098. doi:10.1136/bmjgh-2020-003098
  8. Marmot M. The health gap: the challenge of an unequal world: the argument. Int J Epidemiol. 2017;46(4):1312-1318. doi:10.1093/ije/dyx163
  9. Paul E, Ridde V. Évaluer les effets des différentes mesures de lutte contre le Covid-19, mission impossible? The Conversation; 2020.
  10. Christakis DA, Van Cleve W, Zimmerman FJ. Estimation of US children's educational attainment and years of life lost associated with primary school closures during the coronavirus disease 2019 pandemic. JAMA Netw Open. 2020;3(11):e2028786. doi:10.1001/jamanetworkopen.2020.28786
  11. Schmets G, Rajan D, Kadandale S. Strategizing National Health in the 21st Century: A Handbook. Geneva: World Health Organization; 2016.
  12. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88. doi:10.1186/s12913-017-2031-8
  13. Daniels N. Accountability for reasonableness. BMJ. 2000;321(7272):1300-1301. doi:10.1136/bmj.321.7272.1300
  14. Rajan D, Koch K, Rohrer K, et al. Governance of the Covid-19 response: a call for more inclusive and transparent decision-making. BMJ Glob Health. 2020;5(5). doi:10.1136/bmjgh-2020-002655
  15. Mercatelli D, Giorgi FM. Geographic and genomic distribution of SARS-CoV-2 mutations. Front Microbiol. 2020;11:1800. doi:10.3389/fmicb.2020.01800
  16. Day T, Gandon S, Lion S, Otto SP. On the evolutionary epidemiology of SARS-CoV-2. Curr Biol. 2020;30(15):R849-R857. doi:10.1016/j.cub.2020.06.031
  17. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-1501.e1415. doi:10.1016/j.cell.2020.05.015
  18. Wadman M. Hidden immune weakness found in 14% of gravely ill COVID-19 patients. Science. 2020. doi:10.1126/science.abe9395
  19. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782-793. doi:10.1001/jama.2020.12839
  20. Wise J. Covid-19: study reveals six clusters of symptoms that could be used as a clinical prediction tool. BMJ. 2020;370:m2911. doi:10.1136/bmj.m2911
  21. O'Driscoll M, Dos Santos GR, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020. doi:10.1038/s41586-020-2918-0
  22. Ioannidis JPA. The infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ; 2020. https://www.who.int/bulletin/online_first/BLT.20.265892.pdf.
  23. Centers for Disease Control and Prevention (CDC). Disease Burden of Influenza. https://www.cdc.gov/flu/about/burden/index.html.
  24. Kouadio IK, Kamigaki T, Oshitani H. Measles outbreaks in displaced populations: a review of transmission, morbidity and mortality associated factors. BMC Int Health Hum Rights. 2010;10:5. doi:10.1186/1472-698x-10-5
  25. Fan G, Yang Z, Lin Q, Zhao S, Yang L, He D. Decreased case fatality rate of COVID-19 in the second wave: a study in 53 countries or regions. Transbound Emerg Dis. 2020. doi:10.1111/tbed.13819
  26. Van Damme W, Dahake R, van de Pas R, Vanham G, Assefa Y. COVID-19: does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics? SSRN. July 3, 2020. doi:10.2139/ssrn.3649975
  27. Bustos Sierra N, Bossuyt N, Braeye T, et al. All-cause mortality supports the COVID-19 mortality in Belgium and comparison with major fatal events of the last century. Arch Public Health. 2020;78:117. doi:10.1186/s13690-020-00496-x
  28. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4
  29. Mallapaty S. The coronavirus is most deadly if you are older and male-new data reveal the risks. Nature. 2020;585(7823):16-17. doi:10.1038/d41586-020-02483-2
  30. Lin TPH, Wan KH, Huang SS, Jonas JB, Hui DSC, Lam DSC. Death tolls of COVID-19: where come the fallacies and ways to make them more accurate. Glob Public Health. 2020;15(10):1582-1587. doi:10.1080/17441692.2020.1808040
  31. 31 Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L, Taylor DDH. Excess deaths from COVID-19 and other causes, March-July 2020. JAMA. 2020;324(15):1562-1564. doi:10.1001/jama.2020.19545
  32. Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Netw Open. 2020;3(9):e2019722. doi:10.1001/jamanetworkopen.2020.19722
  33. Benskin LL. A basic review of the preliminary evidence that COVID-19 risk and severity is increased in vitamin D deficiency. Front Public Health. 2020;8:513. doi:10.3389/fpubh.2020.00513
  34. Paul E, Brown GW, Ridde V. COVID-19: time for paradigm shift in the nexus between local, national and global health. BMJ Glob Health. 2020;5(4):e002622. doi:10.1136/bmjgh-2020-002622
  35. McCartney M. We need better evidence on non-drug interventions for covid-19. BMJ. 2020;370:m3473. doi:10.1136/bmj.m3473
  36. Campeau L, Degroote S, Ridde V, Carabali M, Zinszer K. Containment measures for emerging and re-emerging vector-borne and other infectious diseases of poverty in urban settings: a scoping review. Infect Dis Poverty. 2018;7(1):95. doi:10.1186/s40249-018-0478-4
  37. Kalk A, Schultz A. SARS-CoV-2 epidemic in African countries-are we losing perspective? Lancet Infect Dis. 2020. doi:10.1016/s1473-3099(20)30563-6
  38. Henley J. Sweden Spared European Surge as Coronavirus Infections Stay Low. The Guardian.  September 15, 2020. https://www.theguardian.com/world/2020/sep/15/sweden-records-its-fewest-daily-covid-19-cases-since-march.
  39. Rutter H, Wolpert M, Greenhalgh T. Managing uncertainty in the covid-19 era. The BMJ Opinion. Published July 22, 2020. https://blogs.bmj.com/bmj/2020/07/22/managing-uncertainty-in-the-covid-19-era.
  40. Smith K, Cairney P. Welcome to the Evidence & Policy blog: Our Reflections on the Field. Evidence & Policy Blog; 2020. https://evidenceandpolicyblog.co.uk/2020/05/11/welcome-to-the-evidence-policy-blog-our-reflections-on-the-field/.
  41. Sturmberg JP. Health System Redesign: How to Make Health Care Person-Centered, Equitable, and Sustainable. Cham, Switzerland: Springer; 2018.
  42. Bennett JM, Reeves G, Billman GE, Sturmberg JP. Inflammation-Nature's way to efficiently respond to all types of challenges: implications for understanding and managing "the epidemic" of chronic diseases. Front Med (Lausanne). 2018;5:316. doi:10.3389/fmed.2018.00316
  43. Sturmberg JP, Picard M, Aron DC, et al. Health and disease-emergent states resulting from adaptive social and biological network interactions. Front Med (Lausanne). 2019;6:59. doi:10.3389/fmed.2019.00059
  44. Holroyd TA, Oloko OK, Salmon DA, Omer SB, Limaye RJ. Communicating recommendations in public health emergencies: the role of public health authorities. Health Secur. 2020;18(1):21-28. doi:10.1089/hs.2019.0073
  45. Park JJH, Decloedt EH, Rayner CR, Cotton M, Mills EJ. Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. Lancet Glob Health. 2020;8(10):e1249-e1250. doi:10.1016/s2214-109x(20)30365-x
  46. Marquis C, Tilcsik A. Imprinting: toward a multilevel theory. Acad Manag Ann. 2013;7(1):195-245. doi:10.5465/19416520.2013.766076
  47. Alexander G. Institutions, path dependence, and democratic consolidation. J Theor Polit. 2001;13(3):249-269. doi:10.1177/095169280101300302

Articles in Press, Accepted Manuscript
Available Online from 29 November 2020
  • Receive Date: 05 October 2020
  • Revise Date: 19 November 2020
  • Accept Date: 21 November 2020